[NT 10-Q] Esperion Therapeutics, Inc. SEC Filing
Esperion Therapeutics, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 because it has not completed its quarter-end financial close. Management identified errors in an earnings release previously furnished and subsequently amended; the amended release contains preliminary, unaudited financial data based on management estimates that remain subject to completion of closing procedures. The Company requires additional time to finalize its condensed financial statements.
Esperion states it expects to file the Form 10-Q as soon as practicable and no later than the five-calendar-day extension permitted by Rule 12b-25. The filing notes that all other periodic reports for the last 12 months have been filed and that the Company does not anticipate a significant change in results versus the comparable prior-year period. Contact: Sheldon L. Koenig, President and CEO.
Esperion Therapeutics, Inc. ha informato la SEC di non poter depositare in tempo il proprio rapporto trimestrale sul Modulo 10-Q relativo al trimestre chiuso il 30 giugno 2025 perch茅 non ha completato la chiusura contabile di fine trimestre. La direzione ha identificato errori in un comunicato sugli utili precedentemente fornito e successivamente rettificato; il comunicato rettificato contiene dati finanziari preliminari, non revisionati basati su stime della direzione che restano soggette alle procedure di chiusura. La Societ脿 necessita di ulteriore tempo per finalizzare i suoi prospetti finanziari abbreviati.
Esperion dichiara di prevedere di depositare il Modulo 10-Q appena possibile e comunque non oltre l'estensione di cinque giorni di calendario consentita dalla Regola 12b-25. Il deposito indica che tutti gli altri rapporti periodici degli ultimi 12 mesi sono stati presentati e che la Societ脿 non prevede una variazione significativa nei risultati rispetto al periodo comparabile dell'anno precedente. Contatto: Sheldon L. Koenig, Presidente e Amministratore Delegato.
Esperion Therapeutics, Inc. notific贸 a la SEC que no puede presentar a tiempo su Informe Trimestral en el Formulario 10-Q correspondiente al trimestre cerrado el 30 de junio de 2025 porque no ha completado el cierre contable de fin de trimestre. La direcci贸n detect贸 errores en un comunicado de resultados previamente entregado y posteriormente enmendado; el comunicado enmendado contiene datos financieros preliminares, no auditados basados en estimaciones de la direcci贸n que siguen sujetos a la finalizaci贸n de los procedimientos de cierre. La Compa帽铆a necesita tiempo adicional para finalizar sus estados financieros condensados.
Esperion indica que espera presentar el Formulario 10-Q tan pronto como sea posible y, como m谩ximo, dentro de la pr贸rroga de cinco d铆as calendario permitida por la Norma 12b-25. La presentaci贸n se帽ala que todos los dem谩s informes peri贸dicos de los 煤ltimos 12 meses han sido presentados y que la Compa帽铆a no anticipa un cambio significativo en los resultados respecto al mismo per铆odo del a帽o anterior. Contacto: Sheldon L. Koenig, Presidente y CEO.
Esperion Therapeutics, Inc.電� 攵勱赴 膦呺鞚检澑 2025雲� 6鞗� 30鞚�搿� 雭濍倶電� 攵勱赴鞚� 攵勱赴氤搓碃靹�(Form 10-Q)毳� 旮绊暅 雮挫棎 鞝滌稖頃� 靾� 鞐嗠嫟瓿� SEC鞐� 韱奠頄堨姷雼堧嫟. 鞚措姅 攵勱赴毵� 鞛 毵堦皭鞚� 鞕勲霅橃 鞎婌晿旮� 霑岆鞛呺媹雼�. 瓴届榿歆勳潃 鞚挫爠鞐� 鞝滌稖霅橃棃雼り皜 靾橃爼霅� 鞁れ爜 氚滍憸鞐愳劀 鞓る毳� 頇曥澑頄堨溂氅�, 靾橃爼霅� 氚滍憸鞐愲姅 毵堦皭 鞝堨皑 鞕勲 鞝勳澑 瓴届榿歆� 於旍爼鞐� 霐半ジ 鞓堧箘鞝�, 氙戈皭靷� 鞛 雿办澊韯瓣皜 韽暔霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� 鞖旍暯 鞛鞝滍憸毳� 斓滌 頇曥爼頃橁赴 鞙勴暣 於旉皜 鞁滉皠鞚� 頃勳殧頃╇媹雼�.
Esperion鞚� 臧�電ロ暅 頃� 鞁犾啀頌�, 攴鸽Μ瓿� Rule 12b-25臧� 項堨毄頃橂姅 斓滊寑 5鞚� 鞐办灔 鞚措偞鞐� Form 10-Q毳� 鞝滌稖頃� 鞓堨爼鞚措澕瓿� 氚濏様鞀惦媹雼�. 鞚措矆 鞝滌稖靹滌棎電� 歆�雮� 12臧滌洈 霃欖晥鞚� 氇摖 雼るジ 鞝曣赴 氤搓碃靹滊姅 鞝滌稖霅橃棃雼�瓿� 旮办灛霅橃柎 鞛堨溂氅�, 須岇偓電� 鞝勲厔 霃欔赴 雽�牍� 鞁れ爜鞐� 欷戨寑頃� 氤�霃欖澊 鞛堨潉 瓴冹溂搿� 鞓堨儊頃橃 鞎婌姷雼堧嫟. 氍胳潣: Sheldon L. Koenig, 靷灔 瓴� CEO.
Esperion Therapeutics, Inc. a inform茅 la SEC qu'elle ne peut pas d茅poser dans les d茅lais son rapport trimestriel sur le formulaire 10-Q pour le trimestre clos le 30 juin 2025, car la cl么ture comptable de fin de trimestre n'est pas encore achev茅e. La direction a relev茅 des erreurs dans un communiqu茅 de r茅sultats pr茅c茅demment fourni et ensuite corrig茅 ; le communiqu茅 amend茅 contient des donn茅es financi猫res pr茅liminaires, non audit茅es fond茅es sur des estimations de la direction et sujettes 脿 l'ach猫vement des proc茅dures de cl么ture. La Soci茅t茅 a besoin de temps suppl茅mentaire pour finaliser ses 茅tats financiers abr茅g茅s.
Esperion indique qu'elle pr茅voit de d茅poser le formulaire 10-Q d猫s que possible et au plus tard dans le d茅lai de cinq jours calendaires autoris茅 par la r猫gle 12b-25. Le d茅p么t pr茅cise que tous les autres rapports p茅riodiques des 12 derniers mois ont 茅t茅 d茅pos茅s et que la Soci茅t茅 ne pr茅voit pas de changement significatif des r茅sultats par rapport 脿 la m锚me p茅riode de l'ann茅e pr茅c茅dente. Contact : Sheldon L. Koenig, Pr茅sident et PDG.
Esperion Therapeutics, Inc. teilte der SEC mit, dass es seinen Quartalsbericht auf Formular 10-Q f眉r das zum 30. Juni 2025 endende Quartal nicht fristgerecht einreichen kann, da der Quartalsabschluss noch nicht abgeschlossen ist. Das Management hat Fehler in einer zuvor 眉bermittelten und anschlie脽end berichtigen Gewinnmitteilung festgestellt; die berichtigte Mitteilung enth盲lt auf Managementsch盲tzungen basierende vorl盲ufige, ungepr眉fte Finanzdaten, die weiterhin der Abschlusspr眉fung unterliegen. Das Unternehmen ben枚tigt zus盲tzliche Zeit, um seine verk眉rzten Finanzberichte fertigzustellen.
Esperion gibt an, dass es beabsichtigt, das Formular 10-Q so bald wie m枚glich und sp盲testens innerhalb der von Rule 12b-25 erlaubten f眉nf Kalendertage nachzureichen. Die Einreichung weist darauf hin, dass alle anderen periodischen Berichte der letzten 12 Monate eingereicht wurden und dass das Unternehmen nicht von einer wesentlichen Ver盲nderung der Ergebnisse im Vergleich zum entsprechenden Vorjahreszeitraum ausgeht. Kontakt: Sheldon L. Koenig, President und CEO.
- All other periodic reports for the past 12 months have been filed, indicating prior compliance with reporting obligations
- Company intends to file within the five-calendar-day extension allowed by Rule 12b-25, limiting the expected delay window
- Errors were identified in an earnings release that required an amended version, indicating reporting inaccuracies
- Quarter-end financial close is incomplete, preventing timely finalization of condensed financial statements
- Amended earnings release is based on preliminary, unaudited estimates, so reported figures may change when finalized
Insights
TL;DR: Late 10-Q due to incomplete close and corrected earnings release; company expects to use the five-day extension.
Esperion discloses a delayed Form 10-Q for the quarter ended June 30, 2025 because quarter-end close is incomplete and an earnings release required amendment. The Company emphasizes that the amended release contains preliminary, unaudited estimates and that it does not anticipate a significant change versus the comparable period. From a financial-analysis perspective, the disclosure is procedural and the stated expectation to file within the permitted five-calendar-day extension limits near-term reporting disruption, but final condensed financials remain pending and will determine material impact.
TL;DR: Identified errors in an earnings release and an incomplete close raise governance and controls questions that merit attention.
The filing confirms management discovered errors in a previously furnished earnings release and required an amended release; it also reports an incomplete quarter-end close. These facts, as disclosed, suggest weaknesses or lapses in the controls and review processes that produced the initial release. While the Company reports all other periodic filings are current and does not expect a significant change in results, stakeholders should note the underlying correction and delayed close as indicators to monitor the company鈥檚 reporting controls and remediation steps once the finalized 10-Q is filed.
Esperion Therapeutics, Inc. ha informato la SEC di non poter depositare in tempo il proprio rapporto trimestrale sul Modulo 10-Q relativo al trimestre chiuso il 30 giugno 2025 perch茅 non ha completato la chiusura contabile di fine trimestre. La direzione ha identificato errori in un comunicato sugli utili precedentemente fornito e successivamente rettificato; il comunicato rettificato contiene dati finanziari preliminari, non revisionati basati su stime della direzione che restano soggette alle procedure di chiusura. La Societ脿 necessita di ulteriore tempo per finalizzare i suoi prospetti finanziari abbreviati.
Esperion dichiara di prevedere di depositare il Modulo 10-Q appena possibile e comunque non oltre l'estensione di cinque giorni di calendario consentita dalla Regola 12b-25. Il deposito indica che tutti gli altri rapporti periodici degli ultimi 12 mesi sono stati presentati e che la Societ脿 non prevede una variazione significativa nei risultati rispetto al periodo comparabile dell'anno precedente. Contatto: Sheldon L. Koenig, Presidente e Amministratore Delegato.
Esperion Therapeutics, Inc. notific贸 a la SEC que no puede presentar a tiempo su Informe Trimestral en el Formulario 10-Q correspondiente al trimestre cerrado el 30 de junio de 2025 porque no ha completado el cierre contable de fin de trimestre. La direcci贸n detect贸 errores en un comunicado de resultados previamente entregado y posteriormente enmendado; el comunicado enmendado contiene datos financieros preliminares, no auditados basados en estimaciones de la direcci贸n que siguen sujetos a la finalizaci贸n de los procedimientos de cierre. La Compa帽铆a necesita tiempo adicional para finalizar sus estados financieros condensados.
Esperion indica que espera presentar el Formulario 10-Q tan pronto como sea posible y, como m谩ximo, dentro de la pr贸rroga de cinco d铆as calendario permitida por la Norma 12b-25. La presentaci贸n se帽ala que todos los dem谩s informes peri贸dicos de los 煤ltimos 12 meses han sido presentados y que la Compa帽铆a no anticipa un cambio significativo en los resultados respecto al mismo per铆odo del a帽o anterior. Contacto: Sheldon L. Koenig, Presidente y CEO.
Esperion Therapeutics, Inc.電� 攵勱赴 膦呺鞚检澑 2025雲� 6鞗� 30鞚�搿� 雭濍倶電� 攵勱赴鞚� 攵勱赴氤搓碃靹�(Form 10-Q)毳� 旮绊暅 雮挫棎 鞝滌稖頃� 靾� 鞐嗠嫟瓿� SEC鞐� 韱奠頄堨姷雼堧嫟. 鞚措姅 攵勱赴毵� 鞛 毵堦皭鞚� 鞕勲霅橃 鞎婌晿旮� 霑岆鞛呺媹雼�. 瓴届榿歆勳潃 鞚挫爠鞐� 鞝滌稖霅橃棃雼り皜 靾橃爼霅� 鞁れ爜 氚滍憸鞐愳劀 鞓る毳� 頇曥澑頄堨溂氅�, 靾橃爼霅� 氚滍憸鞐愲姅 毵堦皭 鞝堨皑 鞕勲 鞝勳澑 瓴届榿歆� 於旍爼鞐� 霐半ジ 鞓堧箘鞝�, 氙戈皭靷� 鞛 雿办澊韯瓣皜 韽暔霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� 鞖旍暯 鞛鞝滍憸毳� 斓滌 頇曥爼頃橁赴 鞙勴暣 於旉皜 鞁滉皠鞚� 頃勳殧頃╇媹雼�.
Esperion鞚� 臧�電ロ暅 頃� 鞁犾啀頌�, 攴鸽Μ瓿� Rule 12b-25臧� 項堨毄頃橂姅 斓滊寑 5鞚� 鞐办灔 鞚措偞鞐� Form 10-Q毳� 鞝滌稖頃� 鞓堨爼鞚措澕瓿� 氚濏様鞀惦媹雼�. 鞚措矆 鞝滌稖靹滌棎電� 歆�雮� 12臧滌洈 霃欖晥鞚� 氇摖 雼るジ 鞝曣赴 氤搓碃靹滊姅 鞝滌稖霅橃棃雼�瓿� 旮办灛霅橃柎 鞛堨溂氅�, 須岇偓電� 鞝勲厔 霃欔赴 雽�牍� 鞁れ爜鞐� 欷戨寑頃� 氤�霃欖澊 鞛堨潉 瓴冹溂搿� 鞓堨儊頃橃 鞎婌姷雼堧嫟. 氍胳潣: Sheldon L. Koenig, 靷灔 瓴� CEO.
Esperion Therapeutics, Inc. a inform茅 la SEC qu'elle ne peut pas d茅poser dans les d茅lais son rapport trimestriel sur le formulaire 10-Q pour le trimestre clos le 30 juin 2025, car la cl么ture comptable de fin de trimestre n'est pas encore achev茅e. La direction a relev茅 des erreurs dans un communiqu茅 de r茅sultats pr茅c茅demment fourni et ensuite corrig茅 ; le communiqu茅 amend茅 contient des donn茅es financi猫res pr茅liminaires, non audit茅es fond茅es sur des estimations de la direction et sujettes 脿 l'ach猫vement des proc茅dures de cl么ture. La Soci茅t茅 a besoin de temps suppl茅mentaire pour finaliser ses 茅tats financiers abr茅g茅s.
Esperion indique qu'elle pr茅voit de d茅poser le formulaire 10-Q d猫s que possible et au plus tard dans le d茅lai de cinq jours calendaires autoris茅 par la r猫gle 12b-25. Le d茅p么t pr茅cise que tous les autres rapports p茅riodiques des 12 derniers mois ont 茅t茅 d茅pos茅s et que la Soci茅t茅 ne pr茅voit pas de changement significatif des r茅sultats par rapport 脿 la m锚me p茅riode de l'ann茅e pr茅c茅dente. Contact : Sheldon L. Koenig, Pr茅sident et PDG.
Esperion Therapeutics, Inc. teilte der SEC mit, dass es seinen Quartalsbericht auf Formular 10-Q f眉r das zum 30. Juni 2025 endende Quartal nicht fristgerecht einreichen kann, da der Quartalsabschluss noch nicht abgeschlossen ist. Das Management hat Fehler in einer zuvor 眉bermittelten und anschlie脽end berichtigen Gewinnmitteilung festgestellt; die berichtigte Mitteilung enth盲lt auf Managementsch盲tzungen basierende vorl盲ufige, ungepr眉fte Finanzdaten, die weiterhin der Abschlusspr眉fung unterliegen. Das Unternehmen ben枚tigt zus盲tzliche Zeit, um seine verk眉rzten Finanzberichte fertigzustellen.
Esperion gibt an, dass es beabsichtigt, das Formular 10-Q so bald wie m枚glich und sp盲testens innerhalb der von Rule 12b-25 erlaubten f眉nf Kalendertage nachzureichen. Die Einreichung weist darauf hin, dass alle anderen periodischen Berichte der letzten 12 Monate eingereicht wurden und dass das Unternehmen nicht von einer wesentlichen Ver盲nderung der Ergebnisse im Vergleich zum entsprechenden Vorjahreszeitraum ausgeht. Kontakt: Sheldon L. Koenig, President und CEO.
FAQ
Why did ESPR file a Form 12b-25 (NT 10-Q)?
For which period is Esperion delaying the 10-Q?
When does Esperion expect to file the Form 10-Q?
Was the earnings release corrected and are the numbers final?
Does Esperion anticipate a significant change in results versus the prior year period?
Who can be contacted about this notification?
